Glaukos Corporation $GKOS Shares Sold by Granite Investment Partners LLC

Posted by George Bondi on Jul 9th, 2026

Granite Investment Partners LLC trimmed its position in Glaukos Corporation (NYSE:GKOS – Free Report) by 6.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 111,872 shares of the medical instruments supplier’s stock after selling 7,471 shares during the period. Granite Investment Partners LLC’s holdings in Glaukos were worth $12,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the company. First Horizon Corp boosted its holdings in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Glaukos during the fourth quarter worth about $28,000. Larson Financial Group LLC raised its holdings in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Glaukos by 111.4% in the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 215 shares during the period. Finally, Salomon & Ludwin LLC lifted its position in Glaukos by 111.2% in the fourth quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 239 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In other news, Director Leana Wen sold 1,700 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the sale, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. The trade was a 7.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the sale, the director owned 35,528 shares in the company, valued at approximately $5,000,921.28. This represents a 12.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 51,273 shares of company stock worth $7,332,003 over the last quarter. Insiders own 5.90% of the company’s stock.

Glaukos Stock Up 1.5%

Shares of NYSE GKOS opened at $152.89 on Thursday. The stock has a market capitalization of $8.98 billion, a price-to-earnings ratio of -46.61 and a beta of 0.75. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $154.61. The firm has a 50-day moving average price of $131.05 and a 200 day moving average price of $120.19. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS – Get Free Report) last issued its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. During the same period in the prior year, the business posted ($0.22) earnings per share. The firm’s revenue for the quarter was up 41.2% compared to the same quarter last year. Equities research analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GKOS has been the topic of a number of analyst reports. Needham & Company LLC lifted their price objective on Glaukos from $136.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Piper Sandler reissued an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research note on Wednesday, July 1st. HC Wainwright initiated coverage on Glaukos in a report on Monday. They issued a “buy” rating and a $168.00 price target for the company. JPMorgan Chase & Co. lifted their price target on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and an average target price of $151.62.

Read Our Latest Research Report on GKOS

Glaukos Company Profile

(Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.